Anywhere under £45.27, GSK’s share price looks cheap to me

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case.

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK’s (LSE: GSK) share price has traded in an unusually wide range for it over the past year. It recorded a 12-month high of £18.19 on 15 May. And since then hit a one-year low of £13.05 on 18 November. Currently, it is much nearer that low than the high, at just £13.58.

This scale of the loss – 25% at present – flags the possibility to me of a bargain buying opportunity. New shares at such a low price could add value to my existing holding in GSK.

But I need to check that there is value in the stock. Such a fall could also indicate that the company is simply worth less than it was before or that the market is catching up to the true value of the shares.

Are the shares undervalued right now or not?

The first part of my pricing assessment compares GSK’s key valuations with those of its competitors.

On the price-to-earnings ratio, it trades at just 21.6 – bottom of its peer group, which averages 29.1. This comprises Merck KGaA at 22.8, both Zoetis and AstraZeneca at 31, and CSL at 31.4. So, GSK looks very undervalued on that basis.

The same is true on the key price-to-book and price-to-sales ratios. On the former, GSK currently trades at 3.9 against a competitor average of 6.6. And on the latter, it is presently at 1.7 compared to a 5.2 average for its peers.

The second part of my pricing assessment examines where GSK shares should be, based on future cash flow forecasts. This discounted cash flow analysis  shows the stock is 70% undervalued at its current £13.58 price.

Therefore, the fair value of the stock is technically £45.27. Market unpredictability may move it lower or higher than this. But it underlines to me that the stock is absolutely packed with value right now.

How does the core business look?

A steady trickle of bad news has weighed on GSK’s share price over the past 12 months.

Ongoing litigation over its Zantac drug’s link to cancer is one. And this remains a primary risk for the firm, in my view.

The 23 December US Food and Drug Administration’s de-authorisation of for four Covid antibody-based drugs for emergency use is another. This includes GSK’s Sotrovimab.

That said, there have been several positive developments as well. The major one in my view is the $1.15bn acquisition of US biotech firm IDRx announced on 13 January.

It is part of the firm’s strategic shift towards gastrointestinal cancers to compensate for a declining vaccines business.

Factoring in all positive and negative factors to date, analysts forecast GSK’s earnings will increase 20.7% each year to end-2027. And it is this growth that ultimately drives a firm’s share price (and dividend) higher.

Will I buy more shares?

Currently, the yield on GSK shares is 4.3%. But analysts’ forecast it will rise in 2025 to 4.8% and in 2026 to 5.2%. These return rates compare favourably to the FTSE 100 average of 3.6%.

And the stellar earnings growth projections should also drive the share price much higher, in my view.

As such, I will be buying more GSK stock very soon.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Simon Watkins has positions in AstraZeneca Plc and GSK. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

With an 8% yield and a P/E below 12, Taylor Wimpey looks in deep value territory

Harvey Jones wants to make a bit of noise about Taylor Wimpey shares. The FTSE 100 stock may be volatile…

Read more »

A young Asian woman holding up her index finger
Investing Articles

Up 8% today, is this one of the FTSE 100 best growth shares to buy?

Looking for the best FTSE 100 growth shares for a winning portfolio? This soaring blue chip is worth serious consideration,…

Read more »

Investing Articles

With yields over 7%, here are two FTSE 100 dividend shares to consider in 2025

As the FTSE 100 trades near all-time highs in 2025, some of its top dividend shares still offer highly attractive…

Read more »

Investing Articles

Here’s why Coca-Cola HBC stock jumped over 9% in the FTSE 100 today

This stock was flying to a record high in the FTSE 100 today, boosted by a strong set of earnings.…

Read more »

Investing Articles

1 FTSE 100 stock an investor consider for a Stocks and Shares ISA if Cash ISAs get canned

The talk in the papers is of the Cash ISA getting axed, but the Stocks and Shares ISA seems secure.…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

A 5.5% dividend forecast? £2k invested in Lloyds shares could earn an investor this much by 2027

Jon Smith talks through the dividend forecast for Lloyds stock in the coming years and weighs up whether it could…

Read more »

Investing Articles

How much in savings would investors need to target a £3,000 monthly passive income?

Our writer outlines a simple recipe to earn passive income from shares. The ingredients include diligent saving, ample time and…

Read more »

Investing Articles

The average Stocks and Shares ISA turned £10k into £25k in a decade. I aim to beat that

Harvey Jones is impressed by the long-term total return on the average Stocks and Shares ISA. Yet he still reckons…

Read more »